CN104884060A - 治疗方案 - Google Patents

治疗方案 Download PDF

Info

Publication number
CN104884060A
CN104884060A CN201380052215.1A CN201380052215A CN104884060A CN 104884060 A CN104884060 A CN 104884060A CN 201380052215 A CN201380052215 A CN 201380052215A CN 104884060 A CN104884060 A CN 104884060A
Authority
CN
China
Prior art keywords
experimenter
compositions
agonist
kinds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380052215.1A
Other languages
English (en)
Chinese (zh)
Inventor
N·G·希特肯
R·E·派克
J·F·考夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
S1 Pharmaceuticals Inc
Original Assignee
S1 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S1 Pharmaceuticals Inc filed Critical S1 Pharmaceuticals Inc
Priority to CN201710010422.0A priority Critical patent/CN106924259A/zh
Publication of CN104884060A publication Critical patent/CN104884060A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380052215.1A 2012-08-06 2013-08-06 治疗方案 Pending CN104884060A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710010422.0A CN106924259A (zh) 2012-08-06 2013-08-06 治疗方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679999P 2012-08-06 2012-08-06
US61/679,999 2012-08-06
PCT/US2013/053843 WO2014025814A1 (en) 2012-08-06 2013-08-06 Treatment regimens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710010422.0A Division CN106924259A (zh) 2012-08-06 2013-08-06 治疗方案

Publications (1)

Publication Number Publication Date
CN104884060A true CN104884060A (zh) 2015-09-02

Family

ID=50068530

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380052215.1A Pending CN104884060A (zh) 2012-08-06 2013-08-06 治疗方案
CN201710010422.0A Pending CN106924259A (zh) 2012-08-06 2013-08-06 治疗方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710010422.0A Pending CN106924259A (zh) 2012-08-06 2013-08-06 治疗方案

Country Status (15)

Country Link
US (1) US9517254B2 (https=)
EP (1) EP2879680A4 (https=)
JP (2) JP2015524474A (https=)
KR (4) KR20230136142A (https=)
CN (2) CN104884060A (https=)
AU (2) AU2013299725A1 (https=)
BR (1) BR112015002687A2 (https=)
CA (1) CA2881388A1 (https=)
EA (1) EA201590349A1 (https=)
HK (2) HK1211239A1 (https=)
IL (1) IL237150B (https=)
MX (1) MX2015001695A (https=)
SG (3) SG10201709967YA (https=)
WO (1) WO2014025814A1 (https=)
ZA (1) ZA201501562B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36742A (es) * 2016-06-17 2016-12-30 S1 Biopharma Inc Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2025042884A2 (en) * 2023-08-21 2025-02-27 Kuleon Llc Serotonin receptor modulators for the treatment of addictions and overdoses
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687771A (en) * 1985-11-01 1987-08-18 Bristol-Myers Company Method for treatment of male impotence
CN1938040A (zh) * 2003-03-05 2007-03-28 Pr药品有限公司 缩宫素控释制剂及其应用方法
CN1946404A (zh) * 2004-04-22 2007-04-11 贝林格尔·英格海姆国际有限公司 用于治疗性功能疾病ⅱ的新颖药物组合物
WO2011146726A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321965A1 (de) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP2002322085A (ja) * 2001-04-26 2002-11-08 Kazuhito Tomizawa 知的機能障害治療剤
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
AU2005235422B2 (en) 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
US20060004076A1 (en) 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
EP1827450A4 (en) 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
US9023793B2 (en) * 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
WO2008075162A2 (en) * 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
WO2009016488A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd. Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
AU2009282822A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating CNS disorders
EP2389187B1 (en) * 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
WO2012016229A2 (en) * 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose
SG10201609297VA (en) * 2011-04-04 2016-12-29 S1 Biopharma Inc Treatment regimens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687771A (en) * 1985-11-01 1987-08-18 Bristol-Myers Company Method for treatment of male impotence
CN1938040A (zh) * 2003-03-05 2007-03-28 Pr药品有限公司 缩宫素控释制剂及其应用方法
CN1946404A (zh) * 2004-04-22 2007-04-11 贝林格尔·英格海姆国际有限公司 用于治疗性功能疾病ⅱ的新颖药物组合物
WO2011146726A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IXCHEL HERRERA-GUZMÁN: "Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder", 《PSYCHIATRY RESEARCH》 *
JACK G. MODELL ET AL.: "Effect of Bupropion-SR on Orgasmic Dys function in Nondepres sed Subjects: A Pilot Study", 《JOURNAL OF SEX & MARITAL THERAPY》 *
KAI MACDONALD ET AL.: "Dramatic Improvement in Sexual Function Induced by Intranasal Oxytocin", 《INTERNATIONAL SOCIETY FOR SEXUAL MEDICINE》 *
ROBERT TAYLOR SEGRAVES ET AL.: "Bupropion Sustained Release for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women", 《JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY》 *
SANTIAGO MONLEÓN，ET AL: "Antidepressant drugs and memory: Insights from animal studies", 《EUROPEAN NEUROPSYCHOPHARMACOLOGY》 *

Also Published As

Publication number Publication date
KR20200128437A (ko) 2020-11-12
AU2018205121A1 (en) 2018-07-26
CN106924259A (zh) 2017-07-07
AU2013299725A1 (en) 2015-03-26
HK1211239A1 (en) 2016-05-20
SG10201908587PA (en) 2019-10-30
KR20230136142A (ko) 2023-09-26
CA2881388A1 (en) 2014-02-13
ZA201501562B (en) 2017-11-29
EP2879680A4 (en) 2016-06-01
US9517254B2 (en) 2016-12-13
KR20250041078A (ko) 2025-03-25
KR20150063039A (ko) 2015-06-08
IL237150B (en) 2018-07-31
US20150150946A1 (en) 2015-06-04
SG10201709967YA (en) 2018-01-30
WO2014025814A1 (en) 2014-02-13
MX2015001695A (es) 2015-09-28
IL237150A0 (en) 2015-04-30
HK1214505A1 (zh) 2016-07-29
BR112015002687A2 (pt) 2019-12-17
EP2879680A1 (en) 2015-06-10
SG11201500919PA (en) 2015-04-29
JP2018150357A (ja) 2018-09-27
JP2015524474A (ja) 2015-08-24
EA201590349A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
AU2018205121A1 (en) Treatment regimens
AU2018264030A1 (en) Treatment regimens
JP2009500420A (ja) エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
MX2008000248A (es) Combinaciones de eszopiclona y un antidepresivo y metodos de tratamiento contra la menopausia y trastornos del estado de animo, la ansiedad y trastornos cognitivos.
CA2933921A1 (en) Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment
HK1240825A1 (en) Treatment regimens
WO2025245102A2 (en) Methods and compositions for treating sexual disorder, weight loss, weight maintenance, well-being, and self-esteem

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214505

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150902

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1214505

Country of ref document: HK